Pfizer announced that it was withdrawing its application for emergency use authorization (EUA) in India for its COVID-19 vaccine. The pharmaceutical company failed to meet India’s regulatory requirements for a local immunogenicity study to ensure the safety of the vaccine on its population. This mean that for the two most populous countries, India and China, the Pfizer vaccine will not be available. Pfizer released a statement in regards to the decision, “Based on the deliberations at the meeting and our understanding of additional information that the regulator may need, the company has decided to withdraw its application at this time.”
Read more here.